Emerging immunosuppressive drugs in kidney transplantation

Current Clinical Pharmacology

Volumn 6, Issue 2, 2011, Pages 130-136

  Metalidis, Christoph ^a   Kuypers, Dirk R J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Calcineurin inhibitors; Immunosuppressive drugs; Kidney transplantation

Indexed keywords

ALEFACEPT; BELATACEPT; BORTEZOMIB; CALCINEURIN INHIBITOR; ECULIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; SOTRASTAURIN; TASOCITINIB; TOFACITINIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG MEGADOSE; DYSPEPSIA; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; VOMITING;

CALCINEURIN; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PROTEIN KINASE C;

EID: 79959356069     PISSN: 15748847     EISSN: 15748847     Source Type: Journal    
DOI: 10.2174/157488411796151093     Document Type: Review

References (52)

1. Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73: 1923-8.
2. Spitaler M, Cantrell DA. Protein kinase C and beyond. Nat Immunol 2004; 5: 785-90.
3. Volkov Y, Long A, McGrath S, Ni ED, Kelleher D. Crucial importance of PKC-beta(I) in LFA-1-mediated locomotion of activated T cells. Nat Immunol 2001; 2: 508-14.
4. Sun Z, Arendt CW, Ellmeier W, et al. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 2000; 404: 402-7.
5. Wagner J, von MP, Sedrani R, et al. Discovery of 3-(1H-indol-3- yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5 -dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes. J Med Chem 2009; 52: 6193-6.
6. Evenou JP, Wagner J, Zenke G, et al. The potent protein kinase Cselective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation. J Pharmacol Exp Ther 2009; 330: 792-801.
7. Matz M, Weber U, Mashreghi MF, et al. Effects of the new immunosuppressive agent AEB071 on human immune cells. Nephrol Dial Transplant 2010; 25: 2159-67.
8. Bigaud M, Wieczorek G, Riesen S. NVP-AEB071 (AEB), a novel inhibitor of early T-cell activation, prolongs the survival of nonhuman primate kidney allografts when used as monotherapy or at non-effective doses combined with a non-effective dose of cyclosporine (abstract). Am J Transplant 2006; 6(Suppl 2): 250.
9. Kovarik JM, Slade A. Overview of sotrastaurin clinical pharmacokinetics. Ther Drug Monit 2010; 32: 540-3.
10. Kovarik JM, Huang HL, Slade A, Sfikas N, Chandler PA. The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. Br J Clin Pharmacol 2009; 68: 381-5.
11. Kovarik JM, Stitah S, Slade A, et al. Sotrastaurin and tacrolimus coadministration: effects on pharmacokinetics and biomarker responses. J Clin Pharmacol 2010; 50: 1260-6.
12. Abstract American Transplant Congress 2011. 2010. Ref Type: Unpublished Work.
13. Kovarik JM, Stitah S, Slade A, et al. Sotrastaurin and cyclosporine drug interaction study in healthy subjects. Biopharm Drug Dispos 2010; 31: 331-9.
14. Kovarik JM, Bartlett M, Rordorf C, et al. Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. Int J Clin Pharmacol Ther 2010; 48: 103-8.
15. Slade A, Jung T, Dumortier T. Nvp-Aeb071 Maximum Tolerated Dose: Safety and Tolerability of a Novel T-Cell Activation inhibitor: 1216. Transplantation 2008; 86: 412.
16. Friman, S., Arns, W, and Banas, B. AEB071, a novel protein kinase C-inhibitor: evaluation of an AEB071 plus mycophenolate regimen in renal transplant recipients. Am.J.Transplant. 9[suppl.2], 323-324. 2009.
17. Budde K, Sommerer C, Becker T, et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renaltransplant recipients. Am J Transplant 2010; 10: 571-81.
18. Liu KD, Gaffen SL, Goldsmith MA. JAK/STAT signaling by cytokine receptors. Curr Opin Immunol 1998; 10: 271-8.
19. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273-87.
20. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302: 875-8.
21. Borie DC, Changelian PS, Larson MJ, et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 2005; 79: 791-801.
22. Krishnaswami S, Busque S, Leventhal J. Pharmacokinetic profile of CP-690,550 in de novo renal allograft recipients. Transplantation 2008; 86: 414.
23. Weimar W, Duplin M, Gaston R. Multipple dose pharmacokinetics of CP-690,550 in stable renal allograft recipients dosed with CP- 690,550 in combination with other immunosuppressive agents. Transplantation 2006; 82: 900.
24. van Gurp E, Weimar W, Gaston R, et al. Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant 2008; 8: 1711-8.
25. Busque S, Leventhal J, Brennan DC, et al. Calcineurin-inhibitorfree immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant 2009; 9: 1936-45.
26. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991; 147: 2461-6.
27. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-58.
28. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443-53.
29. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-81.
30. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-46.
31. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10:547-557.
32. Larsen CP, Grinyo J, Medina-Pestana J, et al. Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies. Transplantation 2010.
33. Miller GT, Hochman PS, Meier W, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993; 178: 211-22.
34. da Silva AJ, Brickelmaier M, Majeau GR, et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol 2002; 168: 4462-71.
35. Krueger GG. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003; 17(Suppl 2): 17-24.
36. Valujskikh A, Li XC. Frontiers in nephrology: T cell memory as a barrier to transplant tolerance. J Am Soc Nephrol 2007; 18: 2252-61.
37. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994; 152: 2753-67.
38. Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med 2009; 15: 746-9.
39. Shapira MY, Abdul-Hai A, Resnick IB, et al. Alefacept treatment for refractory chronic extensive GVHD. Bone Marrow Transplant 2009; 43: 339-43.
40. Richardson PG, Anderson KC. Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol 2003; 1: 596-600.
41. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748-55.
42. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007; 21: 30-36.
43. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201-9.
44. Curran MP, McKeage K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs 2009; 69: 859-88.
45. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 2008; 86: 1754-61.
46. Idica A, Kaneku H, Everly MJ, et al. Elimination of post-transplant donor-specific HLA antibodies with bortezomib. Clin Transpl 2008; 229-39.
47. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555-61.
48. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046-56.
49. Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and singlechain Fv. Mol Immunol 1996; 33: 1389-401.
50. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25: 1256-64.
51. Stegall MD, Diwan TS, Cornell L. Terminal complement inhibition decreases early acute humoral rejection in sensitized renal transplant recipients. Transplantation 2010; 90: 127.
52. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibodymediated rejection. Am J Transplant 2009; 9: 231-5.